Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Cullinan Therapeutics, Inc. (Nasdaq: CGEM) today announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Applicatio ...
He estimated that the company has spent an average of $500,000 each year over that time trying to stay current and optimize ...
Acceptance of the New Drug Application is based on findings from a phase 2b portion of the open-label REZILIENT1 clinical trial.
Senator Jinggoy Estrada reiterated on Tuesday, April 28, that as far as the 2025 budget Department of Public Works and Highways (DPWH) is concerned, ...
American missile systems were deployed last week to a remote Luzon Strait island 100 miles south of Taiwan as part of ...
PHILADELPHIA, April 28, 2026--iECURE to Present Preliminary Clinical Data from Ongoing OTC-HOPE Trial of ECUR-506 in Neonatal ...
Taking three doses of ibuprofen before the insertion of an intrauterine device reduces pain during the procedure compared ...
Rick Tocchet’s first significant move came in Game 5, inserting Alex Bump for Matvei Michkov. This was a decision that ...
FDA NDA acceptance positions zipalertinib for post-systemic-therapy EGFR ex20ins NSCLC, with a February 27, 2027 PDUFA target ...
In this video, Lukas Delasos, DO, discusses highlights from this year’s International Association for the Study of Lung ...
The Vishay WLKN-000 two-way Wilkinson power divider/combiner operates from 15 GHz to 20 GHz, centered at 18 GHz.
A new review examines how insertion and deletion (indel) errors disrupt data synchronization in modern communication systems.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results